Takeda

News

FDA changes its mind and approves Takeda’s Eohilia

In its second attempt, Takeda has secured FDA approval for Eohilia, which becomes the first and only oral therapy in the US for eosinophilic oesophagitis (EoE).

News

Takeda grabs late-stage haematology drug from Protagonist

Takeda has bolstered its near-term pipeline in rare haematological disorders by licensing rights to a polycythaemia vera (PV) treatment being developed by Protagonist Therapeutics.

R&D

JP Morgan 2024 – Graham Heap

Just over a year ago, Takeda acquired a promising immunotherapy candidate, TAK-279, from Boston-based Nimbus Therapeutics.

News

Takeda gets okay in US for rare blood disorder drug

Patients in the US with ultra-rare blood clotting disorder congenital thrombotic thrombocytopenic purpura (cTTP) have an FDA-approved therapy for the first time, after Tak

News

Takeda bags FDA okay for Fruzaqla in colorectal cancer

The FDA has approved Takeda’s Fruzaqla for a group of patients with relapsed or refractory metastatic colorectal cancer, offering another option for patients who have exha

News

Takeda pulls Exkivity in US after failed confirmatory trial

Takeda has decided to withdraw its cancer drug Exkivity from the market, after a trial that was supposed to confirm its efficacy failed to deliver a positive result.

FDA changes its mind and approves Takeda’s Eohilia

Takeda grabs late-stage haematology drug from Protagonist

JP Morgan 2024 – Graham Heap

Takeda gets okay in US for rare blood disorder drug

Takeda bags FDA okay for Fruzaqla in colorectal cancer

Takeda pulls Exkivity in US after failed confirmatory trial

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

Takeda

Editor's Picks